Role of Vesicular Monoamine Transporter2 (VMAT2) Inhibitors in Hyperkinetic Movement Disorders - A Brief Review
Iranian Journal of Child Neurology,
Vol. 15 No. 3 (2021),
1 July 2021
Hyperkinetic movement disorders are a common group of movement abnormalities in children that defined as repetitive unintended involuntary movements. Major hyperkinetic movements contain tremor, tic, dystonia, myoclonus and chorea. Although, there are frequent drugs that effective on these abnormalities, but some of these are resistant to conventional treatments. Vesicular monoamine transporter2 (VMAT2) inhibitors (Tetrabenazine, Deutetrabenazine and Valbenazine) are new agents that have been introduced in the last decade for treatment some movement disorders in particular tardive dyskinesia, Huntington chorea and Tourette syndrome. In this brief review, we reviewed the role of these drugs on hyperkinetic movement disorders.
- vesicular monoamine transporter2 (VMAT2) inhibitors; Hyperkinetic movements; Dyskinesia; Tetrabenazine; Deutetrabenazine; Valbenazine; Children
How to Cite
1- Sanger TD, Chen D, Fehlings SL, Hallett M, Lang AE, Mink JW, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010; 25(11):1538-49.
2- Singer HS, Mink JW, Gilbert DL, et al. Movement Disorders in Childhood, second ed. Academic Press 2016; London.
3- Nikkhah A, Karimzadeh P, Taghdiri MM, et al. Hyperkinetic Movement Disorders in Children: A Brief Review. Iran J Child Neurol. Spring 2019; 13(2):
4- Sreeram V, Shagufta SH, Kagadkar F. Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management. Cureus 2019; 11(8): e5471.
5- Aquino CCH, Lang AE: Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014, 20:113-7.
6- Paleacu D. Tetrabenazine in the treatment of Huntington's disease. Neuropsychiatr Dis Treat. 2007; 3:545–51.
7- Witter DP, Holbert RC, Suryadevara U: Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients. Expert Opin Pharmacother. 2017, 18:965-72.
8- Jankovic J: Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016, 17:2461-70.
9- Frank S. Tetrabenazine: The first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat. 2010; 6:657–65.
10- Yero T, Rey JA. Tetrabenazine (Xenazine), an FDA-Approved Treatment Option for Huntington's Disease-Related Chorea. P T. 2008; 33:690–4.
11- Samay Jain, Paul E. Greene, Steven J. Frucht. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Movement Disorder Society, 2006.
12- Linda H Poon , Gail A Kang, Audrey J Lee. Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother 2010 Jun; 44(6):1080-9.
13- Miguel R, Mendoca MD, Barbosa R, et al. Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study. Ther Adv Neurol Disord 2017; Vol. 10(2) 81-90.
14- Jankovic, J. and Clarence-Smith, K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert RevNeurother 2011; 11: 1509–1523.
15- Jimenez-Shahed, J. and Jankovic, J. Tetrabenazine for treatment of chorea associated with Huntington disease. Expert Opin Orphan Drugs 2013; 1:423–436.
16- Frank, S. Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group TETRA-HD Investigators Huntington study group. BMC Neurol 2009; 9:62–72.
17- Zaki SA, Lad V, Shanbag P. Quadriparesis and dysarthria due to tetrabenazine therapy in a child with rheumatic chorea. Indian J Pharmacol. 2011 Sep; 43(5):601-2.
18- Geschwind MD, Paras N. Deutetrabenazine for treatment of chorea in Huntington disease. JAMA 2016; 316:33-35.
19- Touma KTB and Scarff JR. Valbenazine and deutetrabenazine for tardive dyskinesia. Innov Clin Neurosci 2018; 15: 13–16.
20- Frank S, Testa CM, Stamler D, et al.: Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016, 316:40-50.
21- Fernandez HH, Factor SA, Hauser RA, et al.: Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017, 88:2003-10.
22- Anderson KE, Stamler D, Davis MD, et al.: Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017, 4:595-604.
23- Hauser RA, Factor SA, Marder SR, et al.: KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017, 174:476- 84.
24- Factor SA, Remington G, Comella CL, et al.: The effects of valbenazine in participants with tardive dyskinesia: Results of the 1-year KINECT 3 extension study. J Clin Psychiat. 2017, 78:1344-50.
25- Müller T: Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Inv Drug. 2015, 24: 737-742.
26- Martino D, Pringsheim TM. Tourette syndrome and other chronic tic disorders: an update on clinical management. Expert Rev Neurother 2018; 18(2):125–137.
27- Niemann N, Jankovic J. Real-World Experience with VMAT2 Inhibitors. Clin Neuropharmacol 2019; 42(2):37-41.
- Abstract Viewed: 714 times